Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D04JPQ
|
||||
| Former ID |
DCL000201
|
||||
| Drug Name |
PSN-101
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Diabetes [ICD9: 253.5, 588.1; ICD10:E23.2, N25.1] | Investigative | [550543] | ||
| Company |
OSI Pharma
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C48H68ClN5O12S2
|
||||
| Canonical SMILES |
CC1=CC2=C(C=C1CC(=O)C3=C(C=CS3)S(=O)(=O)NC4=C(C(=NO4)C)<br />Cl)OCO2.CC(C)C(CC1=CC(=C(C=C1)OC)OCCCOC)CC(C(CC(C(C)C)C<br />(=O)NCC(C)(C)C(=O)N)O)N
|
||||
| InChI |
1S/C30H53N3O6.C18H15ClN2O6S2/c1-19(2)22(14-21-10-11-26(38-8)27(15-21)39-13-9-12-37-7)16-24(31)25(34)17-23(20(3)4)28(35)33-18-30(5,6)29(32)36;1-9-5-13-14(26-8-25-13)7-11(9)6-12(22)17-15(3-4-28-17)29(23,24)21-18-16(19)10(2)20-27-18/h10-11,15,19-20,22-25,34H,9,12-14,16-18,31H2,1-8H3,(H2,32,36)(H,33,35);3-5,7,21H,6,8H2,1-2H3/t22-,23-,24-,25-;/m0./s1
|
||||
| InChIKey |
FVDZRAUCUALTCQ-NATPOTRJSA-N
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID | |||||
| Target and Pathway | |||||
| Target(s) | Glucokinase | Target Info | Activator | [550543] | |
| KEGG Pathway | Glycolysis / Gluconeogenesis | ||||
| Galactose metabolism | |||||
| Starch and sucrose metabolism | |||||
| Amino sugar and nucleotide sugar metabolism | |||||
| Butirosin and neomycin biosynthesis | |||||
| Metabolic pathways | |||||
| Biosynthesis of antibiotics | |||||
| Carbon metabolism | |||||
| Insulin signaling pathway | |||||
| Insulin secretion | |||||
| Prolactin signaling pathway | |||||
| Glucagon signaling pathway | |||||
| Type II diabetes mellitus | |||||
| Maturity onset diabetes of the young | |||||
| Central carbon metabolism in cancer | |||||
| Pathway Interaction Database | FOXA2 and FOXA3 transcription factor networks | ||||
| HIF-1-alpha transcription factor network | |||||
| References | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.